Hypertension as a Predictive Factor for Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib after Progression on Cytokines

Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma

(2011) Petri Bono et al.   ACTA ONCOLOGICA

Hypertension Induced by Vascular Endothelial Growth Factor Signaling Pathway Inhibition: Mechanisms and Potential Use as a Biomarker

(2010) Emily S. Robinson et al.   SEMINARS IN NEPHROLOGY

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma

(2009) P. Bono et al.   ANNALS OF ONCOLOGY

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis

(2009) G. Di Lorenzo et al.   ANNALS OF ONCOLOGY

Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis

(2008) Xiaolei Zhu et al.   ACTA ONCOLOGICA

Hypertension and proteinuria: a class-effect of antiangiogenic therapies

(2008) Vincent Launay-Vacher et al.   ANTI-CANCER DRUGS

Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

(2008) Manuela Schmidinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer

(2008) Giorgio Vittorio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Blood Pressure and Risk of Renal Cell Carcinoma in the European Prospective Investigation into Cancer and Nutrition

(2007) S. Weikert et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY